|
Washington, DC (31 January 2025) – The Society of Interventional Oncology (SIO) announced today at the SIO 2025 Annual Scientific Meeting, the launch of the society's second clinical trial, TRIBUTE: A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy. The TRIBUTE study, a multi-million-dollar project, is also the second multi-industry supported clinical study to be executed by the society since its first announcement of the ACCLAIM Trial in 2021.
The TRIBUTE study is collectively supported by the study’s Exclusive Pioneer Trial Partner, Varian, a Siemens Healthineers Company, the study’s Catalyst Trial Partner, Stryker, Inc., and the study’s Advocate Trial Partner, Boston Scientific Corporation.
This is the first prospective, multi-center study to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in adult patients treated with both percutaneous ablation and palliative radiation therapy (RT) for symptomatic, high-risk metastatic bone lesions. The study was collaboratively designed and developed with the partnership of radiation oncology, which SIO sees as a critical multidisciplinary partner to the success of the study.
The TRIBUTE study clinical leadership will include Jack Jennings, MD, PhD, Professor of Radiology and Orthopedic Surgery at Washington University School of Medicine in St. Louis, Sean Tutton, MD, Professor of Radiology and Orthopedics at the University of California, San Diego, School of Medicine, Clifford Robinson, MD, Professor of Radiation Oncology and Medicine at Washington University School of Medicine in St. Louis, and James Urbanic, MD, Professor of Clinical Radiation Medicine and Applied Sciences at the University of California, San Diego. “The results from the TRIBUTE trial have the potential to reshape treatment guidelines for metastatic bone disease. Research is the cornerstone of progress in interventional oncology, and SIO remains committed to driving groundbreaking efforts that elevate the impact of clinical research in our field,” said Jennings.
Percutaneous ablation and RT have different mechanisms of alleviating pain and causing tumor death that may work synergistically. Radiation therapy is a widely accepted treatment for painful bone metastases and provides palliation of pain for patients. Percutaneous ablation, a minimally invasive therapy for painful metastatic bone disease, can be performed with thermal modalities (e.g., radiofrequency, microwave, cryoablation) and requires minimal recovery. “This approach combines the strengths of both percutaneous ablation and radiation therapy. By leveraging their complementary mechanisms, we can offer patients an effective and minimally invasive treatment option for pain relief and tumor management in metastatic bone disease,” said Tutton.
Muneeb Ahmed, MD, FSIR, is the Chief of Interventional Radiology at Beth Israel Deaconess Medical Center and President of the Society of Interventional Oncology. “The success of studies like TRIBUTE are fueled by strong, long-term collaborations with our multidisciplinary physician colleagues and dedicated industry partners,” said Ahmed. “We deeply value the ongoing commitment of our industry partners, whose investment is vital to advancing these critical research areas. The TRIBUTE study is not just a step forward—it’s a bold leap in SIO’s vision to further establish the interventional oncology specialty, setting an ambitious pace for the entire field to follow.”
The TRIBUTE study is set to launch in 2025 with the enrollment of 120 subjects across sites in the United States.
| 
